Prague 5

• A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced … Ended
  2022-502174-16-00 5 2023-09-13 Macular edema secondary to retinal vein occlusion
• A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary … Ended
  2022-500746-16-00 4 2023-08-11 Geographic Atrophy
• An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa Ended
  2022-502921-16-00 6 2023-07-21 Hemophilia A and B
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S … Ended
  2022-501752-29-00 5 2023-06-15 Hidradenitis Suppurativa
• A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. Ended
  2023-508163-74-00 5 2023-06-12 Major Depressive Disorder
• A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended
  2022-501420-20-00 5 2023-05-17 Severe hypertryglyceridemia
• A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK) Ended
  2022-501078-20-00 4 2023-05-15 Metastatic Castration-resistant Prostate Cancer
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended
  2022-501538-44-00 5 2023-04-25 Atopic Dermatitis
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended
  2022-501540-15-00 5 2023-04-25 Atopic Dermatitis
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended
  2024-515185-13-00 5 2022-12-21 geographic atrophy
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• A phase 2/3 study to evaluate efficacy and clinical benefit of AT-007 with Sorbitol Dehydrogenase (SORD) Deficiency Ended
  2024-518250-16-00 10 2022-10-20 Sorbitol Dehydrogenase (SORD) Deficiency
• A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorect … Ended
  2023-503797-21-00 5 2022-08-10 Metastatic Colorectal Cancer
• This study is to evaluate the safety and pharmacokinetics of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B … Ended
  2023-504795-20-00 3 2022-05-20 Relapsed/Refractory Aggressive Mature B-cell Neoplasms
• A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Ended
  2023-508571-37-00 4 2022-04-29 Geographic atrophy (GA) secondary to Age-related Macular Degeneration
• An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects with Geographic Atrophy Secondary to … Ended
  2024-512945-18-00 5 2021-11-30 Geographic Atrophy Secondary to Age-Related Macular Degeneration
• A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneration Ended
  2024-512880-30-00 5 2021-08-27 Neovascular Age-related Macular Degeneration (wet AMD)
• A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product … Ended
  2024-512123-37-00 5 2021-05-27 Parkinson's disease
• A Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherap … Ended
  2022-501531-16-00 5 2020-01-24 esophageal carcinoma
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• A study to test the safety and efficacy of the drug larotrectinib for the treatment of tumors with NTRK-fusion in children Ended
  2022-502668-20-00 9 2017-04-11 Solid tumors harboring NTRK fusion
• A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym … Ended
  2023-507271-21-00 5 2017-04-11 Follicular Lymphoma
• Pembrolizumab in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma Ended
  2023-507294-18-00 5 2016-09-16 Metastatic renal cell carcinoma

Showing 97–120 of 122 trials